Cardiology
<ѻýҕl class='mpt-top_cat_title_description'>News, opinions and meeting coverage in cardiology.ѻýҕl>
<ѻýҕl>AHA: FDA Drops Clopidogrel Bomb at AHAѻýҕl>
ORLANDO -- The FDA has issued a public health advisory warning patients and physicians that concommitant use of clopidogrel (Plavix) and omeprazole (Prilosec and Prilosec OTC) blunts the antiplatelet effect of clopidogrel, so the combination should be avoided.
Nov 17, 2009
<ѻýҕl>CT Safety Warnings Follow Radiation Overdose Accidentѻýҕl>
Reports of stroke patients who were accidentally exposed to eight times the normal radiation dose during diagnostic CT scans at Cedars-Sinai Medical Center in Los Angeles are prompting safety warnings and soul searching in radiology.
Oct 15, 2009
<ѻýҕl>ESC: Peto Analysis Called Short on Proof of Simvastatin/ Ezetimibe Cancer Safetyѻýҕl>
SEATTLE -- Simvastatin/ezetimibe (Vytorin) may increase the risk of cancer after all, concluded a leading American biostatistician who dismissed as prematurely reassuring an analysis by Richard Peto, Ph.D., F.R.S., that found the link with excess malignancy to be overblown.
Sep 04, 2008
<ѻýҕl>ESC: In CABG versus Stent Trial, the Edge Goes to Bypass ѻýҕl>
MUNICH -- The latest round in the surgeons versus interventional cardiologists appears to have gone to the surgeons. So it would seem from today's roundtable discussion at the European Society of Cardiology meeting here.
Sep 01, 2008
<ѻýҕl>Cardiac Arrest Survivors Can Expect Good Long-term Quality of Lifeѻýҕl>
MARBURG, Germany -- Resuscitated cardiac arrest patients treated in an ICU who leave the hospital without severe neurological disabilities may expect a reasonable quality of life over the next five years, a study found.
Jul 17, 2008
<ѻýҕl>ACC: Senate Probe Finds Evidence that Drug Firms Worked to Delay ENHANCE Resultsѻýҕl>
CHICAGO -- E-mails made public today described outrage more than a year ago by the ENHANCE trial's principal investigator because he perceived that a drugmaker was withholding bad results about ezetimibe/simvastatin (Vytorin) for non-scientific reasons.
Mar 31, 2008
<ѻýҕl>ASNC: Caffeine Screens Before Stress Tests Often Miss Positives
ѻýҕl>
SAN DIEGO -- Routine screening by questionnaire for caffeine intake before pharmacologic cardiac stress testing fails to identify most patients who have detectable serum levels of the stimulant, investigators said here.
Sep 12, 2007
<ѻýҕl>FDA Warns Against Use of Red Yeast Rice Supplementsѻýҕl>
ROCKVILLE, Md. -- The FDA has warned consumers against using three brands of red yeast rice, a product marketed as a natural remedy for high cholesterol, because they may contain lovastatin, the active ingredient in Mevacor.
Aug 10, 2007
<ѻýҕl>Heartburn Remedy May Help Treat Heart Failureѻýҕl>
SUITA CITY, Japan -- Heart failure patients who added 30 mg of Pepcid (famotidine) to standard therapy significantly improved NYHA functional class and reduced plasma B-type natriuretic peptide levels compared with those given 150 mg of teprenone.
Sep 25, 2006
<ѻýҕl>Blood Clots Linked to Alzheimer's and Vascular Dementias
ѻýҕl>
MANCHESTER, England — Spontaneous cerebral blood clots were detected at similar rates in patients with Alzheimer's disease and vascular dementia, suggesting a common pathology and a potentially preventable or treatable cause for some dementias, researchers here said.
Apr 28, 2006
<ѻýҕl>ACP: Garlic, Ginseng, Ginkgo Biloba, and Ginger All Bad Actors with Coumadinѻýҕl>
PHILADELPHIA - When it comes to adverse events associated with Coumadin (warfarin) therapy, beware of herbs and many supplements beginning with the letter G, according to a University of Washington investigator.
Apr 09, 2006
<ѻýҕl>ACC: Coronary Artery Disease Patients Should Have Low LDL Goal
ѻýҕl>
ATLANTA, March 10 - For all patients with stable coronary artery disease (CAD), the goal of therapy should be to get LDL cholesterol lower than 70 mg/dL, said Christie Ballantyne, M.D., director of the center for cardiovascular disease prevention at Baylor College of Medicine in Houston.
Mar 22, 2006
<ѻýҕl>Medicare Will Pay for tPA in Stroke Thrombolysisѻýҕl>
WASHINGTON-Medicare is about to announce that beginning in October it will start paying hospitals for use of the thrombolytic drug tissue plasminogen activator (tPA) for treatment of ischemic stroke, according to published reports.
Aug 04, 2005